KiroVAX 003

Drug Profile

KiroVAX 003

Alternative Names: CT-003; KiroVAX003; TAPA loaded DC vaccine - KiroVAX-003; TAPA loaded dendritic cell vaccine - KiroVAX-003; TAPA pulsed dendritic cell vaccine - KiroVAX-003; TAPA-pulsed DC vaccine - KiroVAX-003; Tumour associated peptide antigen loaded DC vaccine-KiroVAX-003; Tumour associated peptide antigen loaded dendritic cell vaccine - KiroVAX-003; Tumour associated peptide antigen pulsed DC vaccine - KiroVAX-003; Tumour associated peptide antigen pulsed dendritic cell vaccine - KiroVAX-003

Latest Information Update: 15 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 28 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (Intradermal) (NCT02224599)
  • 28 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02224599)
  • 01 Sep 2014 Phase-I clinical trials in Solid tumours in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top